Advances in oncology: Adjuvant chemotherapy for stage II and III colorectal cancer

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 8, 2011, Pages 616-618

  Benson, Al B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; DRUG EFFICACY; GENETIC COUNSELING; GENETIC MARKER; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROGNOSIS; PROGRESSION FREE SURVIVAL; TREATMENT INDICATION; ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; INTERVIEW; MEDICAL RESEARCH; METABOLISM; PATHOLOGY; RISK FACTOR;

ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM STAGING; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053071112     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Clinicaltrials.gov. Oxaliplatin, leucovorin, and fluorouracil with or without bevacizumab in treating patients who have undergone surgery for stage II colon cancer. Identifier: NCT00217737. http://clinicaltrials.gov/ct2/show/NCT00217737.
2. Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22:3408-3419.
3. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.
4. Tejpar S, Saridaki Z, Delorenzi M, et al. Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle. J Natl Cancer Inst. 2011;103:841-844.